Bokf Na Acquires 11,990 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Bokf Na boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 599,500.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,992 shares of the biotechnology company’s stock after acquiring an additional 11,990 shares during the period. Bokf Na’s holdings in Sarepta Therapeutics were worth $1,496,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in SRPT. Brevan Howard Capital Management LP lifted its stake in shares of Sarepta Therapeutics by 36.7% during the 4th quarter. Brevan Howard Capital Management LP now owns 4,985 shares of the biotechnology company’s stock worth $606,000 after buying an additional 1,339 shares during the last quarter. Cantor Fitzgerald L. P. acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $213,000. Captrust Financial Advisors increased its stake in shares of Sarepta Therapeutics by 15.4% during the fourth quarter. Captrust Financial Advisors now owns 4,468 shares of the biotechnology company’s stock worth $543,000 after purchasing an additional 597 shares during the period. Algert Global LLC lifted its holdings in Sarepta Therapeutics by 8.3% during the 4th quarter. Algert Global LLC now owns 74,984 shares of the biotechnology company’s stock worth $9,117,000 after purchasing an additional 5,778 shares during the last quarter. Finally, Alkeon Capital Management LLC boosted its stake in Sarepta Therapeutics by 34.7% in the 4th quarter. Alkeon Capital Management LLC now owns 853,845 shares of the biotechnology company’s stock valued at $103,819,000 after purchasing an additional 220,000 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of recent research reports. Royal Bank of Canada reduced their target price on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating for the company in a research report on Wednesday. Guggenheim lowered their target price on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating on the stock in a report on Wednesday. Needham & Company LLC cut their price target on Sarepta Therapeutics from $183.00 to $125.00 and set a “buy” rating for the company in a research note on Wednesday. Deutsche Bank Aktiengesellschaft lowered their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. Finally, Oppenheimer cut their target price on Sarepta Therapeutics from $184.00 to $123.00 and set an “outperform” rating for the company in a research report on Wednesday. Six research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $131.22.

Insider Buying and Selling

In other news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $36.52 on Friday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a one year low of $35.46 and a one year high of $173.25. The business’s 50 day simple moving average is $68.17 and its 200 day simple moving average is $101.49. The stock has a market capitalization of $3.59 billion, a PE ratio of 29.22 and a beta of 0.85.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The company’s quarterly revenue was up 80.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.73 earnings per share. As a group, research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.